NEW YORK, Aug. 20, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq: NBS ), a leader in the emerging cellular therapy industry, announced today that Dr. Hans Keirstead, President, NeoStem Oncology, will give a company presentation at the Swedish-American Life Science Summit 2014 in Stockholm where the conference's theme is 'The Future of Medicine.'
Dr. Keirstead will provide an overview of the Company's clinical development pipeline with an emphasis on NeoStem's Targeted Cancer Immunotherapy Program that focuses on developing patient-specific immunotherapies for the treatment of late stage cancers, including NeoStem's expected initiation later this year of a pivotal Phase 3 trial for NBS20, its lead product candidate.
Swedish-American Life Science Summit 2014
- Date and Time: Friday, August 22, 2014, 10:30 AM
- Venue: OMX Stockholm, Sweden
- Website: www.salss.com
- Presenter: Dr. Hans Keirstead
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
About NBS20
NeoStem expects to initiate a pivotal Phase 3 trial for NBS20, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. The goal of the therapy is to eliminate or neutralize the tumor cells that are responsible for recurrence after medically induced tumor regression after a patient has already had undergone other treatments which may have reduced tumor size, but failed to entirely eliminate the cancer. NBS20 has been the subject of compelling trial results for the treatment of metastatic melanoma. As a result, NBS20 has been approved to enter a Phase 3 clinical trial with Special Protocol Assessment (SPA) and received Fast Track designation for metastatic melanoma, as well as Orphan Drug designation.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Cancer Immunotherapy Program (including whether or not NBS20 will successfully be developed to treat metastatic melanoma or any other cancer indications), Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:
